Skip to Main Content

Among the litany of modest changes that the Trump administration rolled out in its plan to lower drug prices is one big idea that’s already worrying drug makers: a push to consolidate the two disparate Medicare programs that pay for prescription drugs.

Health and Human Services Secretary Alex Azar has been touting the idea all week as a way to bring the negotiating power of the Part D program, which covers seniors’ prescription drugs, into the Part B program, which covers other treatments. “Let me be really clear about this: We are going to bring negotiation to Part B drugs, and we are going to give Part D plans more bargaining power. It’s going to happen,” he said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • There is no reason not to and multiple reasons we should IF there are negotiations going on with Big Pharma to reduce drug prices for our Healthcare. The fact that we, Americans, should pay more than others countries is PRICE GAUGING. That should be against the law..if it’s not already.

Comments are closed.